Table 1 Demographics and baseline characteristics of study participants

Gender (% (n))

 Male

50 (15)

60 (9)

40 (6)

 Female

50 (15)

40 (6)

60 (9)

Age (year (± SD))

47 (±18.8)

45 (±19.8)

48 (±18.2)

Race (% (n))

 Caucasian

77 (23)

73 (11)

80 (12)

 African/American

20 (6)

20 (3)

20 (3)

 Others

3 (1)

7 (1)

-

Disease category (% (n))

 Category 1: active without treatment

23 (7)

20 (3)

27 (4)

 Category 2: active with treatment

50 (15)

60 (9)

40 (6)

 Category 3: inactive with treatment

27 (8)

20 (3)

33 (5)

Anatomical location (% (n))

 Intermediate

30 (9)

33 (5)

27 (4)

 Posterior

60 (18)

60 (9)

60 (9)

 Panuveitis

10 (3)

7 (1)

13 (2)

Underlying disease (% (n))

 Birdshot choroidopathy

13 (4)

7 (1)

20 (3)

 Sarcoidosis

13 (4)

-

27 (4)

 Punctate inner choroidopathy

7 (2)

7 (1)

7 (1)

 Multifocal choroiditis

7 (2)

13 (2)

-

 Vogt-Koyanagi-Harada

3 (1)

7 (1)

-

 Idiopathic

57 (17)

67 (10)

47 (7)

Macular thickness (CMT)

 Macular edema (% (n))

37 (11)

47 (7)

27 (4)

 Central macular thickness (mean ± SD)

356 ± 149

377 ± 178

334 ± 116

 CMT in patients without ME (mean ± SD)

269 ± 28

257 ± 31.6

278 ± 22.5

 CMT in patients with ME (mean ± SD)

505 ± 156

515 ± 176

488 ± 134

Corticosteroid use (% (n))

67 (22)

80 (12)

67 (10)

Corticosteroid dose (mg/day)

 Category 1 (mean ± SD)

NA

NA

NA

 Category 2 (mean ± SD)

28.2 ± 16.2

28.3 ± 18

27.9 ± 14.9

 Category 3 (mean ± SD)

7.1 ± 3.0

7.3 ± 2.1

7.0 ± 4.0

Prior IMT use (% (n))

25 (7)

20 (3)

27 (4)

VA in ETDRS score (Snellen equivalent)

 Category 1 (mean ± SD)

62 ± 13 (20/63)

55 ± 6.2 (20/80)

68 ± 15.4 (20/40)

 Category 2 (mean ± SD)

70 ± 17 (20/40)

66 ± 16.8 (20/50)

75 ± 18.9 (20/32)

 Category 3 (mean ± SD)

72 ± 23 (20/40)

66 ± 23.1 (20/50)

75 ± 24.2 (20/32)